AllianceBernstein
BMY.RT

AllianceBernstein’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

AllianceBernstein’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-101,737
Closed -$70K – 3370
2020
Q4 		$70K Sell
101,737
-50,105
-33% -$107K ﹤0.01% 3130
2020
Q3 		$342K Buy
151,842
+87,492
+136% +$250K ﹤0.01% 2740
2020
Q2 		$230K Buy
+64,350
New +$232K ﹤0.01% 2967

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

AllianceBernstein's BMY.RT Position: Q1 2021 in Review

AllianceBernstein sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 101,737 shares — an estimated $70K sold.

AllianceBernstein first reported a position in BMY.RT in Q2 2020 and held it in 3 quarters. The position peaked at $342K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • AllianceBernstein reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • AllianceBernstein sold 101,737 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $70K.
  • AllianceBernstein first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 3 quarters.
  • AllianceBernstein's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $342K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on AllianceBernstein's 13F filing for Q1 2021, filed 6 May 2021.